Skip to main content

Table 4 Evolution of gastrointestinal toxicity, anticipatory/associative intolerance and behavioral symptoms

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Months na MISS O MTX intolerance Anticipatory and/or associative symptoms Gastrointestinal toxicity Behavioral symptoms
   n (%) n (%) n (%) n (%) n (%)
3 53 19(3.8 %) 10 (18.5 %) 11 (20.8 %) 16 (30.2 %) 31 (58.5 %)
6 54 13 (24.1 %) 14 (25.5 %) 16 (29.6 %) 25 (46.3 %) 33 (66.1 %)
9 49 17 (34.7 %) 14 (28.0 %) 13 (26.5 %) 20 (40.8 %) 27 (55.1 %)
12 49 18 (36.7 %) 15 (30.6 %) 9 (18.4 %) 16 (32.7 %) 28 (57.1 %)
  1. MISS, Methotrexate Intolerance Severity Score
  2. aMISS not available for 2 patients at Month 3. In subsequent months numbers reduced by patients who withdrew (n = 5), in 1 patient MISS at 9 and 12 months not available